Wegovy Pill UK: Everything You Need to Know
Suggested meta description (150 characters): The Wegovy pill has been approved in the UK. Here’s what’s been announced about the oral semaglutide tablet, its licence, trial data and availability.
Suggested URL slug: /wegovy-pill-uk
The Wegovy pill made headlines across the UK when, on 11 June 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) approved oral semaglutide for weight management — making Britain the first country in Europe to license a GLP-1 tablet for weight loss. Until now, semaglutide for weight management has only been available as a weekly injection, so the announcement has generated a huge amount of interest and, inevitably, a fair bit of confusion.
This article rounds up what has actually been announced: what the tablet is, what the regulator’s licence covers, what the published trial data reported, and where things stand on availability. It’s an overview of publicly available information, not medical advice — decisions about any weight loss medication sit between a patient and their own prescriber.
What Is the Wegovy Pill?
The Wegovy pill is a once-daily tablet containing semaglutide, the same active ingredient used in the Wegovy injection. Semaglutide is a GLP-1 receptor agonist — a class of medicine that mimics a natural gut hormone involved in appetite regulation. The science isn’t new; what’s new is the format. The recently licensed tablet delivers semaglutide at a 25mg daily dose, replacing the weekly self-injection with something taken by mouth each morning.
One point of frequent confusion is worth clearing up early. This is not Rybelsus under a new name. Rybelsus is a lower-dose oral semaglutide (up to 14mg) that has been licensed in the UK for some time, but only for type 2 diabetes. The Wegovy pill holds a separate licence, at a higher dose, specifically for weight management. Two different products, two different indications — even though the active ingredient is the same.
Is the Wegovy Pill Available in the UK Yet?
The Wegovy pill has been approved, but approval and availability aren’t the same thing. In its launch announcement, Novo Nordisk — the Danish manufacturer behind Wegovy — said it expects the tablet to reach the UK market through private prescription during the second half of 2026, following a similar path to the one the Wegovy and Mounjaro injections took when they first arrived.
What about the NHS? Not yet. Before any NHS rollout can happen, the National Institute for Health and Care Excellence (NICE) has to complete its own appraisal and decide whether to recommend the tablet for NHS funding. That process is ongoing, no timeline has been confirmed, and industry commentary suggests NHS access is unlikely during 2026. For the moment, the only route is a private prescription issued after an individual clinical assessment.
Who Is the Wegovy Pill Licensed For?
The Wegovy pill’s UK licence covers adults using the medication alongside a reduced-calorie diet and increased physical activity, where they have either a BMI of 30 or above, or a BMI between 27 and 30 together with at least one weight-related health condition — examples commonly cited include high blood pressure, type 2 diabetes and obstructive sleep apnoea.
It’s worth stressing that a licence describes who a medicine may be prescribed to, not who it should be prescribed to. Regulated providers carry out a full assessment covering medical history, existing medications and individual risk factors before deciding whether any GLP-1 medicine is appropriate for a particular person. Meeting a BMI figure on paper is only the starting point of that conversation.
How Is the Wegovy Pill Taken?
The Wegovy pill comes with an unusually specific set of instructions in its official guidance, and there’s an interesting bit of science behind them. Semaglutide is a large molecule that would ordinarily be broken down in the stomach, so the tablet is formulated with an absorption enhancer called SNAC that helps the drug pass through the stomach lining. Food and fluid interfere with that process — which is why the product information states the tablet should be taken on an empty stomach, first thing in the morning, with only a small sip of plain water, followed by a wait of at least 30 minutes before eating, drinking or taking other medicines.
As with the injectable version, published guidance describes a gradual dose escalation over several months rather than starting at the full 25mg. The specifics of any individual’s dosing schedule are set by their prescriber and the patient information leaflet, not by articles like this one.
What Did the Wegovy Pill Trials Show?
The Wegovy pill’s approval was based on the OASIS clinical trial programme, which studied oral semaglutide in adults living with obesity. In the OASIS 4 trial, published in the New England Journal of Medicine, participants taking the 25mg daily tablet alongside lifestyle support recorded an average reduction of 16.6% of their starting body weight over 64 weeks among those who remained on treatment. The published data also reported improvements in blood sugar markers and cardiovascular risk factors such as cholesterol.
Those figures are broadly in line with what earlier trials reported for the weekly semaglutide injection — which is largely why the approval attracted so much attention. It’s the first time a weight loss tablet has produced injection-level results in a licensed UK product. As with all trial data, the numbers describe averages across a study population under trial conditions; they don’t predict any individual’s outcome.
What Side Effects Are Listed for the Wegovy Pill?
The Wegovy pill carries the side effect profile associated with semaglutide generally, and the official product information lists gastrointestinal symptoms as the most common: nausea, vomiting, diarrhoea and constipation, particularly when starting treatment or increasing the dose.
The safety information also references less common but more serious risks — including pancreatitis and gallbladder problems — along with groups for whom semaglutide is not recommended, such as during pregnancy. The MHRA asks anyone who suspects a side effect to report it through its Yellow Card scheme. The full picture is set out in the patient information leaflet, and anyone considering treatment would discuss their individual suitability with a prescriber. That layer of medical oversight is precisely why GLP-1 medicines are prescription-only in the UK.
Beyond the officially listed effects, users of GLP-1 medicines have widely reported other experiences that come with rapid weight loss itself — from digestive quirks like sulfur burps to temporary hair shedding, a phenomenon associated with quick weight reduction on any regimen rather than with one specific drug.
Wegovy Pill vs Wegovy Injection: What’s the Difference?
The Wegovy pill and the Wegovy injection contain the same active ingredient, and the trial data for each reports similar levels of average weight loss — so the practical differences come down to format rather than the medicine itself.
The tablet is taken daily and requires the strict empty-stomach routine described above, but involves no needles and no refrigerated pens. The injection is taken once weekly, with no timing restrictions around food, but remains a self-administered injection. (Worth noting: Mounjaro, the other widely discussed weight loss medicine in the UK, contains a different active ingredient — tirzepatide — and remains injection-only for now. We’ve covered how Mounjaro works and what users commonly experience separately.) Media coverage since the approval has generally framed the choice as one of lifestyle fit — which format someone is realistically able to stick to — rather than one being superior to the other. That’s ultimately a discussion for each patient and their prescriber.
Wegovy Pill Safety: A Note on Where People Buy It
The Wegovy pill’s launch is expected to trigger the same problem that followed the injections: counterfeit and unlicensed products sold through social media and unregulated websites. UK regulators have repeatedly warned about fake semaglutide in circulation, and a tablet is even harder for a buyer to verify than a branded injection pen.
The only legitimate route to any prescription-only medicine in the UK is through a regulated pharmacy or clinic, following a genuine consultation. Any seller offering the Wegovy pill with no questions asked is, by definition, operating outside that system.
Wegovy Pill FAQs
Is the Wegovy pill approved in the UK? Yes. The Wegovy pill was approved by the MHRA on 11 June 2026 for weight management, making it the first oral GLP-1 medicine licensed for weight loss in the UK.
Is the Wegovy pill available on the NHS? Not at the time of writing. The tablet is expected to launch via private prescription while NICE carries out its appraisal, and no date has been confirmed for NHS access.
Is the Wegovy pill the same as Rybelsus? No. Both contain oral semaglutide, but Rybelsus is licensed for type 2 diabetes at doses up to 14mg, while the Wegovy pill is separately licensed for weight management at 25mg.
What weight loss did the Wegovy pill trials report? The OASIS 4 trial reported an average loss of 16.6% of body weight over 64 weeks in participants taking the 25mg tablet alongside lifestyle changes. Individual outcomes vary.
Do you need a prescription for the Wegovy pill? Yes. The Wegovy pill is a prescription-only medicine in the UK and can only be legally supplied following an assessment by a qualified prescriber.
Sources
- MHRA / GOV.UK — First GLP-1 tablet for weight loss approved in the UK (11 June 2026)
- Novo Nordisk — Wegovy® pill approval announcement (11 June 2026)
- Wharton S, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. NEJM 2025;393:1077–1087
- OASIS 4 trial record — ClinicalTrials.gov NCT05564117
- The Pharmaceutical Journal — MHRA approves semaglutide oral tablets for weight loss
- MHRA Yellow Card scheme
This article is for general information only and summarises publicly available announcements and published trial data. It is not medical advice, and nothing here should be used to start, stop or change any medication. Anyone considering weight loss treatment should speak to their GP, pharmacist or a qualified prescriber.
Leave a Reply